David Dandy, PhD

Dr. Dandy has patented and licensed several technologies, and is a founding member of the CSU-affiliated startup company Burst Diagnostics. His expertise in microfluidic platforms has been invaluable in creating point of care bioassay diagnostics.  Generally, his work focuses on the implementation of microfluidic network (μFN) platforms for the development of new bioassays and diagnostics in micro total analytical systems (μTAS).

Dr. Dandy joined Colorado State University in 1992. His research has focused on several areas of microfluidic platforms, with a primary focus in bioassays with specialization in viral and bacteria frameworks. Dr. Dandy has several different themes within his research, including thermal and plasma assisted chemical vapor deposition (CVD) of thin films, superparamagnetic nanoparticle-based detection of Category A and B bioterrorism agents, enzymatic detection of halogenated organic compounds, and microfluidic capillary electrophoretic detection of prion protein. The Bioanalytical Microfluidics Program (Dandy Lab) also works on application of dense medium plasma technology to contaminant degradation and inactivation of viral and bacterial agents, and the study of non-aqueous phase liquid transport in heterogeneous subsurface aquifers.